Pharma Horizons: the future of cell and gene therapy
By European Pharmaceutical Review
19 May 2025
Shares
This exclusive report addresses the key challenges and breakthroughs shaping the future of cell and gene therapy, from QC and analytical development to advanced manufacturing strategies. Discover practical solutions you can implement to drive progress for your organisation.
As emerging technologies reshape the landscape, the cell and gene therapy sector faces complex challenges from supply chain disruptions and cost pressures to regulatory demands and manufacturing bottlenecks.
Inside this report:
Explore how leaders and innovators are tackling the industry’s pressing issues:
- Key trends shaping the future of cell and gene therapy
- Tech-driven advances in biomanufacturing for cell therapies
- Navigating aseptic validation to ensure compliance and efficiency
- PAT implementation in Europe for cost-effective production
- Streamlining mycoplasma testing with Biofire® solutions
- Optimising CMC and quality control for regenerative medicine
- Improving analytical strategies to support gene therapy development
- Overcoming commercialisation hurdles in a competitive market
Leading industry contributors include:
- Van Hoang, SVP, Head of Analytical and QC, Spark Therapeutics
- Patrick Mahieux, Head of Cell and Gene, Europe, SK pharmteco
- Kevin Bruce, Chief Technology and Strategy Officer, Roslin CT
- Rao Kandula, PhD, Head of CMC and Richard Ong, Head of Quality, Medipost.
Download the full report now to discover strategies, tools and innovations that are transforming cell and gene therapy, and learn how to position your organisation for long-term success.
Unlock the full report and discover more >>
This Pharma Horizons report is brought to you in association with:
